Pharco Pharmaceuticals   Report issue

For profit Phase 2 Phase 3
Founded: Alexandria Egypt (1984)
Status: No NME R&D (1984)

Organization Overview

First Clinical Trial
2011
NCT01529710
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Pharco Pharmaceuticals

Active Ingredients

Drugs in Phase 3 Trials (4)

myrrha (commiphora myrrha) (1 trial)

ravidasvir (1 trial)

ribavirin (virazole) (2 trials)

sofosbuvir (sovaldi) (2 trials)

Drugs in Phase 2 Trials (1)

selenious acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Hepatitis, Chronic (Phase 3)

Schistosomiasis (Phase 3)

Schistosomiasis haematobia (Phase 3)

Schistosomiasis mansoni (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 5